文献速递系统性红斑狼疮

泛欧洲系统性红斑狼疮队列中狼疮低疾病活动状态(LLDAS)与DORIS缓解的全血转录组通路分子特征

Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.
PubMed 文献 · Ann Rheum Dis · 2024-06-12

基于PRECISESADS项目321例系统性红斑狼疮患者,分析LLDAS与DORIS缓解对比活动期的差异表达通路,发现604条通路在LLDAS与非LLDAS间显著差异,288条在DORIS缓解者与非缓解者间显著差异,LLDAS与DORIS缓解间无显著差异通路,提示LLDAS从生物学角度是可接受的治疗目标。

要点

  • 321例中40.8%达LLDAS,17.4%达DORIS缓解,排除缓解者后28.3%达LLDAS。
  • LLDAS与非LLDAS间604条通路显著差异(q<0.05,dr≥0.36)。
  • DORIS缓解者与非缓解者间288条通路显著差异(q<0.05,dr≥0.36)。

核心结论

  • 首次证明LLDAS/缓解与活动期SLE间存在可区分的分子信号通路。
  • LLDAS/缓解与SLE发病相关生物学过程及特定临床表现的逆转相关。
  • 按缓解状态聚类比按LLDAS聚类更好地分组患者,证实缓解是SLE的最终治疗目标;但两种状态间缺乏实质性通路差异,从生物学角度支持LLDAS作为可接受目标。

研究设计与样本

  • PRECISESADS项目(NTC02890121)中321例SLE患者,按是否满足LLDAS、DORIS缓解及排除缓解的LLDAS标准分层,分析差异表达通路。

主要发现

  • 321例中40.8%处LLDAS,17.4%处DORIS缓解;排除缓解者后28.3%处LLDAS。
  • LLDAS与非LLDAS间604条通路显著差异(q<0.05,dr≥0.36)。
  • DORIS缓解者与非缓解者间288条通路显著差异(q<0.05,dr≥0.36)。
  • 差异表达通路形成不同分子集群,以血清学、肌肉骨骼和肾脏活动度差异为特征。
  • 部分重叠样本分析显示LLDAS与DORIS缓解间无显著差异通路。

关键数值与推荐

  • LLDAS与非LLDAS比较采用错误发现率校正p(q)<0.05且稳健效应量(dr)≥0.36。
  • DORIS缓解者与非缓解者比较采用q<0.05且dr≥0.36。
  • 揭示的药物重定位潜力及活动性SLE重要通路包括toll样受体(TLR)级联、布鲁顿酪氨酸激酶(BTK)活性、细胞毒性T淋巴细胞抗原4(CTLA-4)相关抑制信号及核苷酸结合寡聚化结构域富含亮氨酸重复蛋白3(NLRP3)炎症小体通路。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To unveil biological milieus underlying low disease activity (LDA) and remission versus active systemic lupus erythematosus (SLE). METHODS: We determined differentially expressed pathways (DEPs) in SLE patients from the PRECISESADS project (NTC02890121) stratified into patients fulfilling and not fulfilling the criteria of (1) Lupus LDA State (LLDAS), (2) Definitions of Remission in SLE remission, and (3) LLDAS exclusive of remission. RESULTS: We analysed data from 321 patients; 40.8% were in LLDAS, and 17.4% in DORIS remission. After exclusion of patients in remission, 28.3% were in LLDAS. Overall, 604 pathways differed significantly in LLDAS versus non-LLDAS patients with an false-discovery rate-corrected p (q)<0.05 and a robust effect size (dr)≥0.36. Accordingly, 288 pathways differed significantly between DORIS remitters and non-remitters (q<0.05 and dr≥0.36). DEPs yielded distinct molecular clusters characterised by differential serological, musculoskeletal, and renal activity. Analysis of partially overlapping samples showed no DEPs between LLDAS and DORIS remission. Drug repurposing potentiality for treating SLE was unveiled, as were important pathways underlying active SLE whose modulation could aid attainment of LLDAS/remission, including toll-like receptor (TLR) cascades, Bruton tyrosine kinase (BTK) activity, the cytotoxic T lymphocyte antigen 4 (CTLA-4)-related inhibitory signalling, and the nucleotide-binding oligomerization domain leucine-rich repeat-containing protein 3 (NLRP3) inflammasome pathway. CONCLUSIONS: We demonstrated for the first time molecular signalling pathways distinguishing LLDAS/remission from active SLE. LLDAS/remission was associated with reversal of biological processes related to SLE pathogenesis and specific clinical manifestations. DEP clustering by remission better grouped patients compared with LLDAS, substantiating remission as the ultimate treatment goal in SLE; however, the lack of substantial pathway differentiation between the two states justifies LLDAS as an acceptable goal from a biological perspective.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Parodis I, Lindblom J, Barturen G, et al. Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort. Ann Rheum Dis. 2024. PMID: 38373843. doi:10.1136/ard-2023-224795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。